Screening of RHD fetal genotype in RhD negative women
Authors:
T. Kratochvílová 1
; J. Böhmová 2; V. Durdová 1
; R. Vodička 2; I. Holusková 3; K. Langová 4
; M. Lubušký 1
Authors‘ workplace:
Porodnicko-gynekologická klinika LF UP a FN, Olomouc, přednosta prof. MUDr. R. Pilka, Ph. D.
1; Ústav lékařské genetiky LF UP a FN, Olomouc, přednosta prof. MUDr. M. Procházka, Ph. D.
2; Transfuzní oddělení FN, Olomouc, vedoucí oddělení MUDr. D. Galuszková, Ph. D., MBA
3; Ústav lékařské biofyziky LF UP, Olomouc, přednosta prof. RNDr. H. Kolářová, CSc.
4
Published in:
Ceska Gynekol 2020; 85(3): 156-163
Category:
Original Article
Overview
Objective: In the Czech Republic in all women within a first trimester screening a laboratory testing for RhD blood group from the peripheral blood should be performed. The aim of the screening is to diagnose RhD negative pregnant women, who may be at risk of developing RhD alloimmunization if the fetus is RhD positive. Currently, the prevention of RhD alloimmunization is carried out regardless of the knowledge of RHD fetal status. Already at the beginning of pregnancy it is possible to determine the RHD genotype of the fetus non-invasively due to cell free fetal DNA circulating in maternal peripheral blood detection. The issue of screening examination of fetal RHD genotype is solved worldwide. In some European countries, the examination is routinely established and thus contributes to the optimization of prenatal care for RhD negative pregnant women, immunoglobulin administration is targeted only in pregnancies with RhD positive fetus.
The aim of our study is to evaluate clinical and laboratory effectiveness of fetal RHD genotype screening in RhD negative women by TaqMan Real-time PCR method.
Designe: Prospective cohort study.
Setting: Obstetrics and Gynecology Clinic of the Faculty of Medicine University Palacky and the University Hospital Olomouc; Institute of Medical Genetics of the Faculty of Medicine UP and the University Hospital Olomouc; Transfusion Department of the University Hospital Olomouc; Institute of Biophysics of the Faculty of Medicine UP Olomouc.
Material and methods: In 2011–2015 at the University Hospital Olomouc 337 examinations of RHD fetal genotype were performed in pregnant women in first and second trimester and evaluated by TaqMan Real-time PCR, followed by verification of the newborn RHD genotype.
Results: Methodology of fetal RHD genotype examination is accurate, reliable and useful in clinical practice. The sensitivity was 97.8%. The specificity was 98.7%. When assessing the effectiveness of the introduction of non- -invasive fetal RHD genotype screening in RhD negative women, it is necessary to assess the medical, organizational and economic aspects. More consistent prevention of RhD alloimmunization in the cases actually indicated may reduce the incidence of RhD alloimmunization.
Conclusion: From the medical point of view the RHD genotype determination in all RhD negative women at the beginning of pregnancy seems effective. It allows to diagnose about 40% of pregnancies with RhD negative fetuses that do not require administration of IgG anti-D. IgG anti-D should be administered only in indicated cases. Determination of fetal RHD genotype by using TaqMan Real-time PCR is useful in clinical practice.
Keywords:
pregnancy – RhD negative women – cell free fetal DNA – TaqMan Real-time polymerase chain reaction – fetal RHD genotype – prevention of RhD alloimmunization – immunglobulin (Ig) G anti-D
Sources
1. Böhmová, J., Vodička, R., Lubušký, M., et al. Stanovení RHD genotypu plodu z plazmy periferní krve těhotné ženy a posouzení citlivosti nových diagnostických postupů pro zavedení do klinické praxe. Čes Gynek, 2013, 78(1), s. 32-40.
2. ČGPS ČLS JEP. Zásady dispenzární péče v těhotenství. Doporučený postup. 2019.
3. Chitty, LS., Finning, K., Wade, A., et al. Diagnostic accuracy of routine antenatal determination of fetal RHD status across gestation: population based cohort study. BMJ, 2014, 349, p. 5243– 5243.
4. Clausen, FB., Christiansen, M., Steffensen, R., et al. Report of the first nationally implemented clinical routine screening for fetal RHD in D-pregnant women to ascertain the requirement for antenatal RhD prophylaxis. Transfusion, 2012, 52, p. 752–758.
5. Daniels, G., Bromilow, I. Essential guide to blood group. Blackwell Publishing, 2009.
6. Darlington, M., Carbonne, B., Mailloux, A., et al. Effectiveness and costs of non-invasive foetal RHD genotyping in rhesus-D negative mothers: a French multicentric two-arm study of 850 women. BMC Pregnancy Childbirth, 2018, 18, p. 496.
7. Gregg, AR., Skotko, BG., Benkendorf, JL., et al. Noninvasive prenatal screening for fetal aneuploidy, 2016 update: a position statement of the American College of Medical Genetics and Genomics. Genet Med, 2018, 18, p. 1056–1065.
8. de Haas, M., Thurik, FF., van der Ploeg, CPB., et al. Sensitivity of fetal RHD screening for safe guidance of targeted anti-D immunoglobulin prophylaxis: prospective cohort study of a nationwide programme in the Netherlands. BMJ, 2016, 355.
9. Haimila, K., Sulin, K., Sainio, S., et al. Targeted antenatal anti-D prophylaxis program for RhD-negative pregnant women – outcome of the first two years of a national program in Finland. Acta Obstet Gynecol Scand, 2017, 96, p. 1228–1233.
10. Hromadnikova, I., Vechetova, L., Vlk, R., et al. Non-invasive fetal RHD and RHCE genotyping using real-time PCR testing of maternal plasma in RhD-negative pregnancies. J Histochem Cytochem, 2005, 53, p. 301–305.
11. Johnson, JA., MacDonald, K., Skoll, A., et al. No. 343 Routine non-invasive prenatal prediction of fetal RHD genotype in Canada: The time is here. J Obstet Gynaecol Canada, 2017, 39, p. 366–373.
12. Kenny-Walsh, E. Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. Irish Hepatology Research Group. N Engl J Med, 1998, 340, p. 1228–1233.
13. Kent, J., Farrell, AM., Soothill, P. Routine administration of Anti-D: the ethical case for offering pregnant women fetal RHD genotyping and a review of policy and practice. BMC Pregnan Childbirth, 2014, 14, p. 87.
14. Lo, D., Corbetta, N., Wainscoat, JS., et al. Presence of fetal DNA in maternal plasma and serum. Lancet, 1997, 350, p. 485– 487.
15. Lubušký, M., Procházka, M., Šimetka, O, Holusková I. Doporučení k provádění prevence RhD aloimunizace u RhD negativních žen. Doporučený postup ČGPS ČLS JEP. Čes Gynek, 2013, 78(2), s. 132–133.
16. Minon, JM., Gerard, C., Foidart, JM., et al. Routine fetal RHD genotyping with maternal plasma: a four-year experience in Belgium. Transfusion, 2008, 48, p. 373–381.
17. Moise, K., Gandhi, M., Paladino, T., et al. Circulating cell-free DNA to determine the fetal RHD status in all three trimesters of pregnancy. Obstet Gynecol, 2016, 128, p. 1340–1346.
18. Neovius, M., Tiblad, E., Wikman, A., et al. Cost-effectiveness of first trimester non-invasive fetal RHD screening for targeted antenatal anti-D prophylaxis in RhD-negative pregnant women: a model-based analysis. BJOG, 2016, 12, p. 1337–1346.
19. O’Brien, K., Siassakos, D., Bidgood, K., et al. Reaction to anti-D immunoglobulin – can we manage it? Obstet Med, 2009 2, p. 38–39.
20. Rutkowski, K., Nasser, SM. Management of hypersensitivity reactions to anti-D immunoglobulin preparations. Allergy, 2014, 69, p. 1560–1563.
21. Salomon, LJ., Sotiriadis, A., Wulff, CB., et al. Risk of miscarriage following amniocentesis or chorionic villus sampling: systematic review of literature and updated meta-analysis. Ultrasound Obstet Gynecol, 2019.
22. Soothill, PW., Finning, K., Daniels,G., et al. Use of cffDNA to avoid administration of anti-D to pregnant women when the fetus is RhD-negative: implementation in the NHS. BJOG, 2015, 122, p. 1682–1686.
23. Sørensen, K., Kjeldsen-Kragh, J., Akkök, ÇA., et al. Determination of fetal RHD type in plasma of RhD negative pregnant women. Scand J Clin Laboratory Investigation, 2018, 78, p. 411–416.
24. Sulakvelidze, I., Evans, S., Dolovich, J., et al. Urticaria from allergy to a purified human anti-Rh antibody preparation. Allergy, 1995, 50, p. 981–983.
25. Svobodová, I., Pazourková E., Korabečná, M., et al. Performance of Droplet Digital PCR in Non-Invasive Fetal RHD Genotyping – comparison with a Routine Real-Time PCR based approach. PLOS One, 2015, 10.
26. Teitelbaum, L., Metcalfe, A., Johnson, JM., et al. Costs and benefits of non-invasive fetal RhD determination. Ultrasound Obstet Gynecol, 2015, 45, p. 84–88.
27. Vivanti, A., Benachi, A., Costa, JM., et al. Diagnostic accuracy of fetal rhesus D genotyping using cell-free fetal DNA during the first trimester of pregnancy. Amer J Obstet Gynecol, 2016, 215, p. 606.e1-606.e5.
28. Wikman, AT., Tiblad, E., Reilly, M., et al. Noninvasive single- -exon fetal RHD determination in a routine screening program in early pregnancy: Obstet Gynecol, 2012, 120, p. 227–234.
Labels
Paediatric gynaecology Gynaecology and obstetrics Reproduction medicineArticle was published in
Czech Gynaecology
2020 Issue 3
Most read in this issue
- Native IVF cycle at woman in 46-age with clinical pregnancy
- Prolongated pregnancy: unusual case
- New estrogen-free oral hormonal contraceptive (Estrogene free ill-EFP)
- The role of neutrophils in preeclampsia